Pharmaceutical Technology6 天
Acetylcysteine zidrimer by Orpheris for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Amyotrophic Lateral Sclerosis.
Pharmaceutical Technology6 天
Acetylcysteine zidrimer by Orpheris for Alzheimer’s Disease: Likelihood of Approval
Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Alzheimer's Disease.
搜狐25 天
揭秘PAMAM-Ce6：生物医学应用潜力无穷的复合材料
近年来，随着生物医学领域的迅速发展，各种新型材料不断涌现，推动着医疗技术的革新。其中，PAMAM-Ce6复合材料凭借其独特的特性，正在受到越来越多的关注。这种材料究竟具备哪些潜力、如何影响生物医学的进展？本文将深入探讨这一备受瞩目的复合材料。